Humeral head replacement in a hemophilia B omarthritis patient

doi:10.3969/j.issn.2095-4344.2016.31.005

Abstract

Abstract:

BACKGROUND: In the past, the surgical treatment of patients with hemophilia B was difficult, the bleeding was difficult to estimate, and the wound healing was difficult. In the perioperative period, the control of coagulation factor IX activity in a safe range can ensure the safety of the operation, resulting in well wound healing, good recovery, and no significant complications appeared in the long term.

OBJECTIVE: To study essentials of perioperative diagnosis and treatment in omarthritis patients with hemophilia B undergoing humeral head replacement, and to analyze the importance on prognosis and rehabilitation.

METHODS: The significance of surgical treatment for hemophilia B patients with arthritis, the prevention and treatment of perioperative complications were summarized through literature review. Humeral head replacement was conducted in a patient with hemophilia omarthritis by monitoring coagulation factor activity and infusing human prothrombin complex and frozen plasma.

RESULTS AND CONCLUSION: (1) According to the monitoring, patients, whose coagulation factor IX activity increased from 7% to 50%, underwent humeral head replacement. (2) Within three days after replacement, coagulation factor IX activity was controlled > 30%, 3 days-2 weeks > 20%. No obvious complication was found after surgery. (3) These results suggested that hemophilia B arthritis was commonly treated by surgical treatment, which plays an important role in assessing patient’s condition and treatment. During perioperative period, replacement therapy of human prothrombin complex and control of coagulation factor activity in a appropriate range can effectively prevent postoperative complications.

中国组织工程研究杂志出版内容重点：人工关节；骨植入物；脊柱；骨折；内固定；数字化骨科；组织工程

Key words: Arthroplasty, Replacement, Prosthesis Implantation, Shoulder Joint, Arthritis, Tissue Engineering

CLC Number:

R318

Qi Wei-zhong, Lin Li-jun, Li Qi. Humeral head replacement in a hemophilia B omarthritis patient[J]. Chinese Journal of Tissue Engineering Research, 2016, 20(31): 4596-4602.

Figures/Tables 1

References

[1] 6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates. Transfus Med Hemother. 2009;36(6):409-418.
[2] 刘颖,陈丽霞.血友病患者日常生活活动能力及其影响因素分析[J]. 中华物理医学与康复杂志, 2013, 35(3): 205-208.
[3] Acharya SS. Exploration of the pathogenesis of haemophilic joint arthropathy: understanding implications for optimal clinical management. Br J Haematol. 2012;156(1):13-23.
[4] Roosendaal G, Lafeber FP. Pathogenesis of haemophilic arthropathy. Haemophilia. 2006;12 Suppl 3:117-121.
[5] Yoo MC, Cho YJ, Kim KI, et al. The outcome of cementless total hip arthroplasty in haemophilic hip arthropathy. Haemophilia. 2009;15(3):766-773.
[6] 李斌.血友病的综合治疗[J]. 血栓与止血学, 2011, 17(2): 88-91.
[7] 焦丽华,代旭兰,刘文芳.凝血酶原复合物的制备及其临床应用进展[J].中国输血杂志, 2008, 21(9):737-741.
[8] Sørensen B, Spahn DR, Innerhofer P, et al. Clinical review: Prothrombin complex concentrates--evaluation of safety and thrombogenicity. Critical Care. 2011; 15(1):201.
[9] Majeed A, Eelde A, Ågren A, et al. Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy. Thromb Res. 2012;129(2):146-151.
[10] Seitz R, Dodt J. Virus safety of prothrombin complex concentrates and factor IX concentrates. Thromb Res. 1999;95(4 Suppl 1):S19-23.
[11] Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia. 2008;14(4):671-684.
[12] Yoshitake S, Schach BG, Foster DC, et al. Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry. 1985;24(14): 3736-3750.
[13] Shapiro AD, Ragni MV, Valentino LA, et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood. 2012; 119(3):666-672.
[14] Roth DA, Kessler CM, Pasi KJ, et al. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood. 2001; 98(13):3600-3606.
[15] 王朝荣.乙型血友病患者的治疗进展[J]. 国际输血及血液学杂志, 2013, 36(2):147-150.
[16] Takedani H, Shima M, Horikoshi Y, et al. Ten-year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan. Haemophilia. 2015;21(3):374-379.
[17] Thompson AR. Structure, function, and molecular defects of factor IX. Blood. 1986;67(3):565-572.
[18] Hirosawa S, Fahner JB, Salier JP, et al. Structural and functional basis of the developmental regulation of human coagulation factor IX gene: factor IX Leyden. Proc Natl Acad Sci U S A. 1990;87(12):4421-4425.
[19] Nishimura H, Takeya H, Miyata T, et al. Factor IX Fukuoka. Substitution of ASN92 by His in the second epidermal growth factor-like domain results in defective interaction with factors VIIa/X. J Biol Chem. 1993;268(32):24041-24046.
[20] 陈金中, 薛京伦. 中国血友病B生物基因治疗研究状况[J]. 科学通报, 2009,54(18):2766-2770.
[21] Wang L, Calcedo R, Wang H, et al. The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques. Mol Ther. 2010;18(1):126-134.
[22] Bigger BW, Siapati EK, Mistry A, et al. Permanent partial phenotypic correction and tolerance in a mouse model of hemophilia B by stem cell gene delivery of human factor IX. Gene Ther. 2006;13(2):117-126.
[23] Mingozzi F, Chen Y, Murphy SL, et al. Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B. Mol Ther. 2012;20(7):1410-1416.
[24] Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365(25): 2357-2365.
[25] Zhang J, Xu L, Haskins ME, et al. Neonatal gene transfer with a retroviral vector results in tolerance to human factor IX in mice and dogs. Blood. 2004;103(1): 143-151.
[26] 中国医学会血液学会血栓与止血学组. 血友病诊断与治疗中国专家共识[J]. 中华血液学杂志, 2011, 32(3) 212-213.
[27] Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet. 2003;361(9371):1801-1809.
[28] Rodriguez-Merchan EC. Aspects of current management: orthopaedic surgery in haemophilia. Haemophilia. 2012;18(1):8-16.
[29] Miles J, Goddard NJ. The impact of haemophilia on the success of total hip arthroplasty. Haemophilia. 2008; 14(1): 81-84.
[30] Wang K, Street A, Dowrick A, et al. Clinical outcomes and patient satisfaction following total joint replacement in haemophilia--23-year experience in knees, hips and elbows. Haemophilia. 2012;18(1): 797-798.